Clinical Trial Update: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT [Phase 2]

View source ↗

Summary

Phase 2 trial of sirolimus and mycophenolate mofetil as graft-versus-host disease prophylaxis in myeloablative, matched related donor hematopoietic cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hodgkin Lymphoma
• Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Rapamune (sirolimus)

Snippet

Sponsor: Stanford University | Conditions: Hematologic Diseases, Acute-graft-versus-host Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-06-05